Sorafenib remains standard therapy for advanced hepatocellular carcinoma

Sorafenib should remain standard therapy for patients with advanced hepatocellular carcinoma, following the negative results of the SEARCH clinical trial, researchers believe.

Liver cancer: standard treatment for hepatocellular carcinoma unchanged (photo: SPL)
Liver cancer: standard treatment for hepatocellular carcinoma unchanged (photo: SPL)

The SEARCH trial looked at 720 patients who were randomised 1:1 to receive either erlotinib and sorafenib or sorafenib plus placebo.

The primary endpoint of the phase III  randomised, double-blind, placebo-controlled trial was a 33% increase in the overall survival on the combination treatment in comparison to sorafenib/placebo.

Personalised medicines, access to cancer drugs and to palliative care are the main issues faced by oncology patients and their healthcare professionals in Europe and worldwide, according to the organisers of the 2012 meeting of the European Society of Medical Oncology.

According to a study from Oxford University annual healthcare costs per head of population for cancer range from 32 to 165 euros across EU countries.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Under 40s to be offered alternative to AstraZeneca COVID-19 vaccine

Under 40s to be offered alternative to AstraZeneca COVID-19 vaccine

Patients aged 30-39 will be offered an alternative to the Oxford/AstraZeneca COVID-19...

GPs per patient down 10% in just five years, NHS data reveal

GPs per patient down 10% in just five years, NHS data reveal

The number of fully-qualified, full-time equivalent (FTE) GPs per patient in England...

Supportive model must replace harmful CQC inspections, BMA chair warns

Supportive model must replace harmful CQC inspections, BMA chair warns

CQC inspections that ‘divert time away from patient care’ and ‘instil fear’ among...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

A 'tsunami' of work is drowning general practice: GPs speak out about a profession at its limit

A 'tsunami' of work is drowning general practice: GPs speak out about a profession at its limit

Rocketing workloads created by huge backlogs of cases and continuing COVID-19 disruption...

Slight increase in GP workforce during past year, but number of partners continues to fall

Slight increase in GP workforce during past year, but number of partners continues to fall

The GP workforce grew by 0.4% in the year to March 2021, but the number of GP partners...